These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32936950)

  • 1. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
    Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
    Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
    Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
    Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
    J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
    Sommer U; Eckstein M; Ammann J; Braunschweig T; Macher-Göppinger S; Schwamborn K; Hieke-Schulz S; Harlow G; Flores M; Wullich B; Wirth M; Roth W; Knüchel R; Weichert W; Baretton G; Hartmann A
    Clin Genitourin Cancer; 2020 Oct; 18(5):e629-e642. PubMed ID: 32178978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
    Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB;
    Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
    Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
    Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
    J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
    Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
    Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
    Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability.
    Ahn S; Woo JW; Kim H; Cho EY; Kim A; Kim JY; Kim C; Lee HJ; Lee JS; Bae YK; Kwon Y; Kim WS; Park SY
    J Breast Cancer; 2021 Jun; 24(3):266-279. PubMed ID: 34128367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
    Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
    Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
    Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
    Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
    Lee SE; Park HY; Lim SD; Han HS; Yoo YB; Kim WS
    J Breast Cancer; 2020 Jun; 23(3):303-313. PubMed ID: 32595992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
    Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
    Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.
    Munari E; Querzoli G; Brunelli M; Marconi M; Sommaggio M; Cocchi MA; Martignoni G; Netto GJ; Caliò A; Quatrini L; Mariotti FR; Luchini C; Girolami I; Eccher A; Segala D; Ciompi F; Zamboni G; Moretta L; Bogina G
    Front Immunol; 2022; 13():954910. PubMed ID: 35967344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
    Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
    Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
    Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
    Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.
    Shi L; Zhang SJ; Chen J; Lu SX; Fan XJ; Tong JH; Chow C; Tin EK; Chan SL; Chong CC; Lai PB; To KF; Wong N; Chan AW
    Mod Pathol; 2019 Nov; 32(11):1646-1656. PubMed ID: 31231126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.